Arsanis has raised $76.0M in total across 3 funding rounds.
Arsanis's investors include Flagship Ventures, NanoDimension, OrbiMed, Polaris Partners, Timothy A. Springer, Atlas Venture, SV Health Investors.
Arsanis was a biotechnology company founded in 2010, focused on developing anti-infective monoclonal antibody therapeutics targeting severe infectious diseases, such as those caused by antibiotic-resistant pathogens, in immunocompromised patients, or with high mortality rates despite low resistance.[1][2] It addressed critical gaps in infectious disease treatment where conventional antibiotics were failing, serving vulnerable patient populations like those with life-threatening infections.[1] The company raised $96.14M across 7 funding rounds, including a $40M IPO in 2017, before completing a reverse merger with X4 Pharmaceuticals on March 13, 2019, after which it ceased independent operations.[2][3][4]
Arsanis emerged in fall 2010 from the vision of founders Dr. Eszter Nagy (former SVP of Research at Intercell AG), Dr. Tillman Gerngross (Co-founder/CEO of Adimab and Co-founder/CSO of GlycoFi, acquired by Merck), and Errik Anderson (Co-founder/COO of Adimab), combining expertise in monoclonal antibody discovery, infectious disease biology, and commercialization.[1] The idea stemmed from the urgent need for new modalities amid rising antibiotic resistance, with Nagy emphasizing monoclonal antibodies' potential role; operations began in Vienna, Austria, supported by Series A financing from OrbiMed Advisors, Polaris Venture Partners, and SV.[1][2] Early traction included pre-clinical proof-of-concept programs, evolving from Austrian roots to U.S. headquarters in Waltham, MA, culminating in an IPO and eventual merger with X4 Pharmaceuticals in 2019.[1][2][3]
Arsanis rode the early 2010s wave of antibody therapeutics amid escalating global antibiotic resistance, a trend amplified by superbugs and failing conventional drugs, aligning with biotech shifts toward precision immunology.[1] Its timing capitalized on post-2000s antibody successes (e.g., via Merck acquisitions), influencing the ecosystem by validating anti-infective mAbs as viable for high-unmet-need areas and attracting VC like OrbiMed/Polaris.[1][4] The 2019 merger with X4 Pharmaceuticals exemplified biotech consolidation, where promising platforms integrate into larger entities to sustain development, contributing to the sector's evolution from standalone startups to networked survivors in a capital-intensive field.[3]
Post-merger, Arsanis as an independent entity ended in 2019, with its legacy absorbed into X4 Pharmaceuticals (now trackable at x4pharma.com), shifting focus from standalone anti-infectives to X4's immunology pipeline.[3] Rising antimicrobial resistance and mAb advancements will likely amplify demand for such innovations, potentially evolving Arsanis's foundational tech through X4 or successors. Its story underscores biotech's high-stakes path: from Vienna garage to IPO and merger, highlighting how targeted science fuels ecosystem resilience amid clinical and funding hurdles—much like the infectious threats it once aimed to conquer.[1][3]
Arsanis has raised $76.0M across 3 funding rounds. Most recently, it raised $46.0M Series D in April 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2017 | $46.0M Series D | Flagship Ventures, NanoDimension, OrbiMed, Polaris Partners, Timothy A. Springer | |
| Sep 1, 2013 | $20.0M Series B | Flagship Ventures, NanoDimension, OrbiMed, Polaris Partners, Timothy A. Springer | |
| Feb 1, 2011 | $10.0M Series A | Atlas Venture, Flagship Ventures, NanoDimension, OrbiMed, Polaris Partners, SV Health Investors, Timothy A. Springer |
